Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Moderna Inc. (MRNA)

160.07   -7.45 (-4.45%) 01-21 18:30
Open: 166.23 Pre. Close: 167.52
High: 171.2543 Low: 157.29
Volume: 11,679,187 Market Cap: 64,900M
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, Metagenomi, Inc., and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd.; Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group; Aldevron, LLC; Institute for Life Changing Medicines; and AbCellera Biologics Inc. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 172.368 - 174.022 174.022 - 175.023
Low: 153.966 - 156.011 156.011 - 157.248
Close: 157.712 - 161.06 161.06 - 163.084

Technical analysis

as of: 2022-01-21 4:28:34 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 302.10     One year: 375.28
Support: Support1: 157.29    Support2: 130.87
Resistance: Resistance1: 258.65    Resistance2: 321.30
Pivot: 209.89
Moving Average: MA(5): 178.60     MA(20): 219.31
MA(100): 307.41     MA(250): 253.69
MACD: MACD(12,26): -25.33     Signal(9): -19.95
Stochastic oscillator: %K(14,3): 1.63     %D(3): 2.10
RSI: RSI(14): 24.62
52-week: High: 497.49  Low: 117.34  Change(%): 2.8
Average Vol(K): 3-Month: 12004  10-Days: 9737

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
MRNA has closed above bottom band by 2.2%. Bollinger Bands are 3.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 21 Jan 2022
U.S. studies highlight the need for COVID boosters to fight Omicron - Nasdaq

Fri, 21 Jan 2022
Moderna's stock has tumbled enough for a long-time bear to say stop selling - MarketWatch

Wed, 19 Jan 2022
Early Omicron Breakthroughs Show mRNA Vaccines' Weakness - Bloomberg

Tue, 18 Jan 2022
Why BioNTech, Moderna, and Novavax Stocks Are Sinking Today - Nasdaq

Mon, 10 Jan 2022
Moderna Announces Advances Across Its Industry-Leading mRNA Pipeline and Provides Business Update - Yahoo Finance

Mon, 10 Jan 2022
Moderna, Inc. (MRNA) CEO Stephane Bancel on JPMorgan 40th Annual Healthcare Conference (Transcript) - Seeking Alpha

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Outperform Price to Earnings: Outperform
Return on Equity: Outperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 405
Shares Float (M) 367
% Held by Insiders 9.49
% Held by Institutions 61.16
Shares Short (K) 16,690
Shares Short P. Month (K) 15,290

Stock Financials

EPS 16.690
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 25.000
Profit Margin 59.68
Operating Margin 64.33
Return on Assets (ttm) 37.2
Return on Equity (ttm) 109.6
Qtrly Rev. Growth 3065.0
Gross Profit (p.s.) -1.418
Sales Per Share 29.177
EBITDA (p.s.) 19.164
Qtrly Earnings Growth
Operating Cash Flow (M) 11,570
Levered Free Cash Flow (M) 8,940

Stock Valuations

PE Ratio 9.59
PEG Ratio
Price to Book value 6.40
Price to Sales 5.49
Price to Cash Flow

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.